The Role of Immunoglobulins in Neonatal Rhesus Haemolytic Disease

Filbey D, Hanson U, Wesstrom G. The prevalence of red cell antibodies in pregnancy correlated to the outcome of the newborn: a 12 year study in central Sweden. Acta Obstet Gynecol Scand 1995; 74: 687–92 Clarke C, Hussey RMSO. Decline in deaths from rhesus haemolytic disease of the newborn. J R Coll Physicians Lond 1994; 28(4): 310–1 Whitfield CR, Raffat A, Urbaniak S. Underreporting of mortality from RhD haemolytic disease in Scotland and its implications: retrospective review. Br Med J 1997; 315(7121): 1504–5 Newman TB, Klebanoff MA. Neonatal hyperbilirubinemia and long term outcome: another look at the collaborative perinatal project. Pediatrics 1993; 92: 651–7 Stewart G, Day RE, Del Priore C, et al. Developmental outcome after intravascular intrauterine transfusion for rhesus haemolytic disease. Arch Dis Child 1994; 70(1): F52–3 Johnston WH, Angara V, Baumal R, et al. Erythroblastosis fetalis and hyperbilirubinaemia: a five-year follow up with neurological psychological and audiological evaluation. Pediatrics 1967; 39(1): 88–92 Nilsen ST, Finne PH, Bergsjo P, et al. Males with neonatal hyperbilirubinaemia examined at 18 years of age. Acta Paediatr Scand 1984; 73(2): 176–180 Craig S, Morris K, Tubman T, et al. The fetal and neonatal outcomes of Rhesus D antibody affected pregnancies in Northern Ireland. Ir Med J 2000; 93(1): 17–8 Greenough A, Yüksel B, Nicolaides KH. Abnormalities of lung volume at follow up following antenatal rhesus iso-immunization. Acta Paediatr 1994; 83: 498–500 Chamberlain D, Hislop A, Hey E, et al. Pulmonary hypoplasia in babies with severe rhesus isoimmunisation: a quantitative study. J Pathol 1977; 122(1): 43–52 Mollison PL, Engelfreit CP, Contreras M. Blood transfusion in clinical medicine. 10th ed. Oford: Blackwell Scientific Publications, 1993 Standing Medical Advisory Committee (SMAC). Memorandum on Haemolytic Disease of the Newborn Addendum 1981. Lndon: Department of Health and Social Security, 1982 Joint Working Group of the British Transfusion Society and the Royal College of Obstetricians and Gynaecologists. Recommendations for the use anti-D immunoglobulin for Rh prophylaxis. Transfus Med 1999; 9: 93–7 Crowther C, Middleton P. Anti-D administration after childbirth for preventing Rhesus alloimmunisation (Cochrane review). In: The Cochrane Library. Issue 3. Oford: Update Software,2000 Tovey LAD. Towards the conquest of Rh haemolytic disease: Britain’s contribution and the role of serendipity. Transfus Med 1992; 2: 99–109 Howard HL, Martlew VJ, McFayen IR, et al. Preventing Rhesus D haemolytic disease of the newborn by giving anti-D immunoglobulin: are the guidelines being adequately followed? Br J Obstet Gynaecol 1997; 104: 37–41 NTBS Immunoglobulin Working Party. Recommendations for use of anti D immunoglobulin. Prescribers Journal 1991; 31: 137–45 Bowman JM, Chown JM, Lewis M, et al. Rh-immunization during pregnancy: antenatal prophylaxis. Can Med Assoc J 1978; 118:623–7 Tovey LAD, Townley A, Stevenson BJ, et al. The Yorkshire antenatal anti D immunoglobulin trial in primigravida. Lancet 1983; 2: 244–6 Huchet J, Dallemagne S, Huchet C, et al. Ante-partum administration of preventive treatment of Rh-D immunization in rhesus-negative women. Parallel evaluation of transplacental passage of fetal blood cells. Results of a multicenter study carried out in the Paris region [French]. J Gynecol Obstet Biol Reprod (Paris) 1987; 16(1): 101–11 Lee D, Rawlinson VI. Multicentre trial of antepartum low-dose anti-D immunoglobulin. Transfus Med 1995; 5(1): 15–9 Proceedings of the Joint Royal College of Physicians of Edinburgh and the Royal College of Obstetricians and Gynaecologists Consensus Conference on Anti D Prophylaxis; 1997 Apr 8–9; Edinburgh. Br J Obstet Gynaecol 1997; 105 (17 Suppl.) Hartwell EA. Use of Rhimmune globulin. Am J Clin Path 1998; 110:281–92 Robson SC, Lee D, Urbaniak S. Anti-D immunoglobulin in RhD prophylaxis. Br J Obstet Gynaecol 1998; 105: 129–34 Adams MM, Marks JS, Koplan JP. Cost implications of routine antenatal administration of Rh immune globulin. Am J Obstet Gynecol 1984; 149: 633–8 Baskett FT, Parson ML. Prevention of rhesus (D) allo immunization: a cost benefit analysis. Can Med Assoc J 1990; 142: 337–9 Selinger M. Immunoprophlaxis for rhesus disease — expensive but worth it? Br J Obstet Gynaecol 1991; 98: 509–12 de Crespigny L, Davison G. Anti-D administration in early pregnancy - time for a new protocol. Aust NZ J Obstet Gynecol 1995; 35(4): 385–7 Watanabe KK, Busch MP, Schrieber GB, et al. Evaluation of safety of Rh immunoglobulin by monitoring viral markers among Rh-negative female blood donors. Vox Sang 2000; 78: 1–6 Tabor E. The epidemiology of virus transmission by plasma derivatives: clinical studies verifying the lack of transmission of hepatitis B and C viruses and HIV type I. Transfusion 1999; 39: 1160–8 Fletcher A, Thomson A. The introduction of human monoclonal anti D for therapeutic use. Transfus Med Rev 1995; 9: 314–26 Armstrong-Fisher SS, Carter MC, Downing I, et al. Evaluation of a panel of human monoclonal antibodies to D and exploration of the synergistic effects of blending IgGl and IgG3 antibodies on their in vitro biologic function. Transfusion 1999; 39(9): 1005–2 Hadley AG. A comparison of in vitro tests for predicting the severity of haemolytic disease of the fetus and newborn. Vox Sang 1998; 74 Suppl. 2: 375–83 Dooren MC, Kuijpers RW, Joekes EC, et al. Protection against immune haemolytic disease of newborn infants by maternal monocyte-reactive IgG alloantibodies (anti-HLA-DR). Lancet 1992; 339: 1067–70 Shepard SL, Noble AL, Filbey D, et al. Inhibition of the monocyte chemiluminescent response to anti-D-sensitized red cells by Fc gamma RI-blocking antibodies which ameliorate the severity of haemolytic disease of the newborn. Vox Sang 1996; 70(3): 157–63 Neppert J, v Witzleben-Schurholz E, Zupanska B, et al. High incidence of maternal HLA A, B and C antibodies associated with a mild course of haemolytic disease of the newborn. Group for the Study of Protective Maternal HLA Antibodies in the Clinical Course of HDN. Eur J Haematol 1999; 63(2): 120–5 Newman TB, Maiseis MJ. Evaluation of jaundice in the term newborn: a kinder, gentler approach. Pediatrics 1992; 89: 809–18 Dodd KL. Neonatal jaundice — a lighter touch. Arch Dis Child 1993; 68: 529–33 Nicolaides KH, Rodeck CH. Maternal serum anti-D antibody concentration and assessment of rhesus isoimmunisation. Br Med J 1992; 304: 1155–6 Nicolini U, Kochenour NK, Greco P, et al. Consequences of fetomaternal haemorrhage after intrauterine transfusion. Br Med J 1988; 297: 1379–81 Mari G, Deter RL, Carpenter RL, et al. Noninvasive diagnosis by Doppler ultrasonography of fetal anemia due to maternal red-cell alloimmunization. Collaborative Group for Doppler Assessment of the Blood Velocity in Anemic Fetuses. N Engl J Med 2000; 342(1): 9–14 Nicolaides KH, Clewell WH, Ibashan RS, et al. Fetal haemoglobin measurement in the assessment of red cell isoimmunisation. Lancet 1988; 1: 1073–5 Gottvall T, Selbing A. Alloimmunization during pregnancy treated with high dose intravenous immunoglobulin. Acta Obstet Gynecol Scand 1995; 74: 777–83 Harman CR. Invasive techniques in the management of allo-immune anaemia. In: Harman CR, editor. Invasive fetal testing and treatment. Boston: Blackwell Scientific, 1995: 107–12 Harman CR, Bowman JM, Manning FA, et al. Intrauterine transfusion — intraperitoneal versus intravascular approach: a case-control comparison. Am J Obstet Gynecol 1990; 162(4): 1053–9 Luban NLC, De Palma L. Transfusion associated graft versus host disease in the neonate — expanding the spectrum of disease. Transfusion 1996; 36: 101–3 Naiman JL, Punnett HH, Lischner HW, et al. Possible graft versus host reaction after intrauterine transfusion for Rh erythroblastosis fetalis. N Engl J Med 1969; 281(13): 697–701 Parkman R, Mosier D, Umansky J, et al. Graft versus host disease after intrauterine and exchange transfusions for haemolytic disease of the newborn. N Engl J Med 1974; 290: 359–63 Scaradavou A, Inglis S, Peterson P, et al. Suppression of erythropoiesis by intrauterine transfusions in hemolytic disease of the newborn: use of erythropoietin to treat the late anemia. J Pediatr 1993; 123: 279–84 Allen FH, Diamond LK, Vaughan VC. Erythroblastosis fetalis VI. Prevention of kernicterus. Am J Dis Child 1950; 80: 779–91 Mollison PL, Walker W. Controlled trials of the treatment of haemolytic disease of the newborn. Lancet 1952; 262: 429 Cochran WD. Increasing safety of exchange transfusion. Pediatr Res 1978; 12:462 Valaes T, Kipouros K, Petmezaki S, et al. Effectiveness and safety of prenatal phenobarbital for the prevention of neonatal jaundice. Pediatr Res 1980; 14: 947–52 Blackburn MG, Orzalesi MM, Pigram P. The combined effect of phototherapy and phenobarbital on serum bilirubin levels of premature infants. Pediatrics 1972; 49(1): 110–2 Valdes OS, Maurer HM, Shumway CN, et al. Controlled clinical trial of phenobarbital and/or light in reducing neonatal hyperbilirubinaemia in a predominantly Negro population. J Pediatr 1971; 79(6): 1015–7 Kappas A, Drummond GS, Manola T, et al. Sn protoporphyrin use in the management of hyperbilirubinaemia in term new-borns with direct Coombs-positive ABO incompatibility. Pediatrics 1988; 81: 485–97 Hayde M, Widness JA, Pollak C, et al. Rhesus isoimmunization: increased hemolysis during early infancy. Pediatr Res 1997; 41(5): 716–21 Kirsten GF, Steyn DW, Muller L, et al. The outcome of babies of mothers with severe rhesus incompatibility treated at Tygerberg Hospital, 1980–1993. S Afr Med J 1995; 85(Suppl. 10): 1091–6 Ennever JF. Blue light, green light, white light, more light: treatment of neonatal jaundice. Clin Perinatol 1990; 17: 467–81 Millard DD, Gidding SS, Socol ML, et al. Effects of intravascular, intrauterine transfusion on prenatal and postnatal haemolysis and erythropoiesis in severe fetal isoimmunisation. J Pediatr 1990; 117: 447–54 Ovali F, Samanci N, Dagoglu T. Management of late anemia in rhesus hemolytic disease: use of recombinant human erythropoietin (a pilot study). Pediatr Res 1996; 39(5): 831–4 Berlin G, Selbing A, Ryden GSO. Rhesus haemolytic disease treated with high-dose intravenous immunoglobulin. Lancet 1985; 1(8438): 1153 Sacker RA, King JC. Intravenous gamma-globulin in pregnancy: a review. Obstet Gynecol 1988; 44: 25–34 de la Camara C, Arrieta R, Gonzalez A, et al. High-dose intravenous immunoglobulin as the sole prenatal treatment for severe Rh immunization. N Engl J Med 1988; 318(8): 519–20 Rewald E. Intravenous gammaglobulin to prevent stillbirth in rhesus incompatibility. Lancet 1985; 2(8448): 208 Chitkara U, Bussel J, Alvarez M, et al. High-dose intravenous gamma globulin: does it have a role in the treatment of severe erythroblastosis fetalis? Obstet Gynecol 1990; 76(4): 703–8 Rewald E, Suringar F. Tolerance of intravenous gamma globulin. Bibl Haematol 1968; 29: 337–9 Urbaniak SJ, Duncan Jl, Armstrong-Fisher SS, et al. Variable inhibition of placental IgG transfer in vitro with commercial rVgG preparations. Br J Haematol 1999; 107: 815–7 Palfi M, Hilden JO, Gottvall T, et al. Placental transport of maternal immunoglobulin G in pregnancies at risk of Rh (D) hemolytic disease of the newborn. Am J Reprod Immunol 1998; 39(5): 323–8 Ulm B, Kirchner L, Svolba G, et al. Immunoglobulin administration to fetuses with anemia due to alloimmunization to D. Transfusion 1999; 39(11-12): 1235–8 Fraser ID, Bothamley JE, Bennett MO, et al. Intensive antenatal plasmapheresis in severe rhesus isoimmunization. Lancet 1976; 1: 6–8 Bowman JM. Hemolytic disease of the newborn. Vox Sang 1996; 70: 62–7 Riibo J, Wahn V High-dose immunoglobulin therapy of hyperbilirubinemia in rhesus incompatibility [German]. Infusionsther Transfusionsmed 1993; 20(Suppl. 1): 104–8; discussion: 109 Derycke M, Dreyfus M, Ropert JC, et al. Intravenous immunoglobulin for neonatal isoimmune thrombocytopenia. Arch Dis Child 1985; 60(7): 667–9 Voto LS, Sexer H, Ferreiro G, et al. Neonatal administration of high dose intravenous immunoglobulin in rhesus hemolytic disease. J Perinat Med 1995; 23: 443–51 Dagoglu T, Ovali F, Samanci N, et al. High-dose intravenous immunoglobulin therapy for rhesus haemolytic disease. J Int Med Res 1995; 23: 264–71 Rübo J, Albrecht K, Lasch P, et al. High dose intravenous immune globulin therapy for hyperbilirubinemia caused by Rh hemolytic disease. J Pediatr 1992; 121: 93–7 Urbaniak SJSO. ADCC (K-cell) lysis of human erythrocytes sensitized with rhesus alloantibodies. II. Investigation into the mechanism of lysis. Br J Haematol 1979; 42(2): 315–25 Massey GV, McWilliams NB, Mueller DG, et al. Intravenous immunoglobulin in treatment of neonatal isoimmune thrombocytopenia. J Pediatr 1987; 111(1): 133–5 Sato K, Hara T, Kondo T, et al. High-dose intravenous gamma-globulin therapy for neonatal immune haemolytic jaundice due to blood group incompatibility. Acta Paediatr Scand 1991; 80: 163–6 Alpay F, Sarici SU, Okutan V, et al. High dose intravenous immunoglobulin therapy in neonatal immune haemolytic jaundice. Acta Paediatr 1999; 88: 216–9 CopeIan EA, Strohm PL, Kennedy MS, et al. Hemolysis following intravenous immune globulin therapy. Transfusion 1986; 26(5): 410–2